Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alessandra Lugaresi, Maria di Ioia, Daniela Travaglini, Erika Pietrolongo, Eugenio Pucci & Marco Onofrj. (2013) Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment 9, pages 893-914.
Read now
Read now
Samaneh Zoghi, Zahra Amirghofran, Alireza Nikseresht, Nahid Ashjazadeh, Eskandar Kamali-Sarvestani & Nahid Rezaei. (2011) Cytokine Secretion Pattern in Treatment of Lymphocytes of Multiple Sclerosis Patients with Fumaric Acid Esters. Immunological Investigations 40:6, pages 581-596.
Read now
Read now
Kenneth P Johnson. (2010) Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Therapeutics and Clinical Risk Management 6, pages 153-172.
Read now
Read now
Alexandra Schröder, Ralf A Linker & Ralf Gold. (2009) Plasmapheresis for neurological disorders. Expert Review of Neurotherapeutics 9:9, pages 1331-1339.
Read now
Read now
Articles from other publishers (19)
F. Piehl. (2020) Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis. Journal of Internal Medicine 289:6, pages 771-791.
Crossref
Crossref
Roberto Motterlini, Aniket Nikam, Sylvie Manin, Anthony Ollivier, Jayne Louise Wilson, Sabrina Djouadi, Lucie Muchova, Thierry Martens, Michael Rivard & Roberta Foresti. (2019) HYCO-3, a dual CO-releaser/Nrf2 activator, reduces tissue inflammation in mice challenged with lipopolysaccharide. Redox Biology 20, pages 334-348.
Crossref
Crossref
Lilla Landeck, Khusru Asadullah, Adriana Amasuno, Ignasi Pau-Charles & Ulrich Mrowietz. (2018) Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data. Archives of Dermatological Research 310:6, pages 475-483.
Crossref
Crossref
Elizabeth A. Mills & Yang Mao-Draayer. (2018) Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View. Frontiers in Immunology 9.
Crossref
Crossref
Sheena L. Dupuy, Shahamat Tauhid, Shelley Hurwitz, Renxin Chu, Fawad Yousuf & Rohit Bakshi. (2016) The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurology and Therapy 5:2, pages 215-229.
Crossref
Crossref
A. Egeberg. (2016) Fumarates for treatment of psoriasis. British Journal of Dermatology 175:5, pages 857-857.
Crossref
Crossref
Zaidoon Al-Jaderi & Azzam A. Maghazachi. (2016) Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases. Frontiers in Immunology 7.
Crossref
Crossref
Elżbieta Miller, Dominika Książek-Winiarek, Tomasz Włodarczyk & Andrzej Głąbiński. 2016. Reactive Oxygen Species in Biology and Human Health. Reactive Oxygen Species in Biology and Human Health
167
185
.
Heidi Vego, Kristin L Sand, Rune A Høglund, Lars-Egil Fallang, Glenn Gundersen, Trygve Holmøy & Azzam A Maghazachi. (2014) Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cellular & Molecular Immunology 13:1, pages 57-64.
Crossref
Crossref
Geoffrey O. Gillard, Brian Collette, John Anderson, Jianhua Chao, Robert H. Scannevin, David J. Huss & Jason D. Fontenot. (2015) DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. Journal of Neuroimmunology 283, pages 74-85.
Crossref
Crossref
Aran Groves, Yasuyuki Kihara & Jerold Chun. (2013) Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. Journal of the Neurological Sciences 328:1-2, pages 9-18.
Crossref
Crossref
Anshul Shakya, Shyam Sunder Chatterjee & Vikas Kumar. (2012) Holistic Psychopharmacology of <i>Fumaria indica</i> (Fumitory). Chinese Medicine 03:04, pages 182-199.
Crossref
Crossref
Alexander Fl?gel, Christian Schl?ger, Fred L?hder & Francesca Odoardi. (2011) Autoimmune disease in the brain ? how to spot the culprits and how to keep them in check. Journal of the Neurological Sciences 311, pages S3-S11.
Crossref
Crossref
Ralf A. Linker, De-Hyung Lee, Sarah Ryan, Anne M. van Dam, Rebecca Conrad, Pradeep Bista, Weike Zeng, Xiaoping Hronowsky, Alex Buko, Sowmya Chollate, Gisa Ellrichmann, Wolfgang Brück, Kate Dawson, Susan Goelz, Stefan Wiese, Robert H. Scannevin, Matvey Lukashev & Ralf Gold. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:3, pages 678-692.
Crossref
Crossref
Gisa Ellrichmann, Elisabeth Petrasch-Parwez, De-Hyung Lee, Christiane Reick, Larissa Arning, Carsten Saft, Ralf Gold & Ralf A. Linker. (2011) Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease. PLoS ONE 6:1, pages e16172.
Crossref
Crossref
Maike M. Schmidt & Ralf Dringen. (2010) Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochemistry International 57:4, pages 460-467.
Crossref
Crossref
Darius Moharregh-Khiabani, Alexander Blank, Thomas Skripuletz, Elvira Miller, Alexandra Kotsiari, Viktoria Gudi & Martin Stangel. (2010) Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse. PLoS ONE 5:7, pages e11769.
Crossref
Crossref
Sabine Amslinger. (2010) The Tunable Functionality of α,β-Unsaturated Carbonyl Compounds Enables Their Differential Application in Biological Systems. ChemMedChem 5:3, pages 351-356.
Crossref
Crossref
MH Han & L Steinman. (2009) Systems biology for identification of molecular networks in multiple sclerosis. Multiple Sclerosis Journal 15:5, pages 529-530.
Crossref
Crossref